Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Gilead To License Hepatitis C Drug

by Lisa M. Jarvis
February 17, 2014 | A version of this story appeared in Volume 92, Issue 7

Gilead Sciences is in negotiations to grant licenses to several Indian generic drug firms to make and sell its hepatitis C virus treatment sofosbuvir in developing countries. A course of treatment with sofosbuvir costs up to $84,000 in the U.S., where it was approved in December 2013. Gilead has said the cost in India for a treatment course would be lowered to roughly $2,000. Doctors Without Borders says the cost for hepatitis C treatment is still “far too high” for people in India and other developing countries and needs to be around $500 to be affordable. Analysts project sales of sofosbuvir to exceed $5 billion in 2014.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.